Cargando…
Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab
Olfactory neuroblastomas (ONBs) are rare malignant tumors that arise from olfactory epithelium and typically present with symptoms attributable to locally invasive disease. Kadish radiographic staging and Hyams' histopathologic grading are prognostic. Overall survival rates, averaging 60–70% at...
Autores principales: | Dunbar, Erin M., Pumphrey, Phyllis K., Bidari, Sharat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401161/ https://www.ncbi.nlm.nih.gov/pubmed/22826790 http://dx.doi.org/10.4081/rt.2012.e33 |
Ejemplares similares
-
Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas
por: Topcagic, Jasmina, et al.
Publicado: (2018) -
Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab
por: Mitsuhashi, Atsushi, et al.
Publicado: (2015) -
Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy
por: Schuster, Cornelia, et al.
Publicado: (2018) -
Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
por: Kanat, Ozkan, et al.
Publicado: (2019) -
Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors
por: Chlenski, Alexandre, et al.
Publicado: (2010)